Jorge Soledad, Swisher Elizabeth M, Norquist Barbara M, Pennington Kathryn P, Gray Heidi J, Urban Renata R, Garcia Rochelle L, Doll Kemi M
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Gynecol Oncol Rep. 2019 Aug 9;29:113-117. doi: 10.1016/j.gore.2019.08.001. eCollection 2019 Aug.
The objectives of this study were to describe the patterns and duration of primary and recurrent treatment in patients with ovarian cancer (OC) harboring germline and () mutations. A retrospective review of mutation carriers with advanced, high-grade OC diagnosed between 2004 and 2014 with at least 3 years of follow-up (or until death) was undertaken. Descriptive statistics were calculated and a Swimmer's Plot used to depict disease course. Forty mutation carriers (26 , 14 ) were identified. Mean age was 54 (range 32-77). All had cytoreductive surgery and received platinum chemotherapy. Median platinum-free interval was 11.9 months (IQR 3.6-21.9). Among 28 patients who recurred, median number of treatment lines was 4 (IQR 3-6), with a median of 2 (IQR 2-3) platinum lines. On average, patients who recurred spent 32% (IQR 20-43%) of their time after diagnosis receiving cytotoxic chemotherapy and 54% (IQR 42-67%) of the time on some cancer-directed therapy, including maintenance. Median overall survival was 79.1 months from diagnosis and 25.4 months after first recurrence. In conclusion, beyond first-line therapy, there was treatment and outcome heterogeneity for -mutated OC. After OC diagnosis, patients spent close to half their life on treatment.
本研究的目的是描述携带种系和（）突变的卵巢癌（OC）患者初次治疗和复发治疗的模式及持续时间。对2004年至2014年间诊断为晚期、高级别OC且至少随访3年（或直至死亡）的突变携带者进行了回顾性分析。计算了描述性统计数据，并使用游程图描绘疾病进程。共识别出40名突变携带者（26名，14名）。平均年龄为54岁（范围32 - 77岁）。所有患者均接受了细胞减灭术并接受了铂类化疗。无铂间期的中位数为11.9个月（四分位间距3.6 - 21.9）。在28例复发患者中，治疗线数的中位数为4（四分位间距3 - 6），铂类治疗线数的中位数为2（四分位间距2 - 3）。平均而言，复发患者在诊断后接受细胞毒性化疗的时间占其总时间的32%（四分位间距20 - 43%），接受包括维持治疗在内的某些针对癌症的治疗的时间占54%（四分位间距42 - 67%）。从诊断开始的总生存期中位数为79.1个月，首次复发后的总生存期中位数为25.4个月。总之，除一线治疗外， -突变型OC存在治疗和结局的异质性。OC诊断后，患者近半生时间都在接受治疗。
